Anika Therapeutics Q4 revenue beats

Anika Therapeutics

26/02/2026 12:18

Overview

Osteoarthritis solutions firm's Q4 revenue flat yr/yr

Commercial Channel revenue grew 22% yr/yr, driven by international shipments and product adoption

Company continues $15 mln share repurchase program, funded $10.7 mln to date

Outlook

Anika expects 2026 revenue between $114 mln and $122.5 mln, up 1% to 9% year over year

Company anticipates 2026 adjusted EBITDA as a percent of revenue to be 5% to 10%

Anika continues $15 mln share repurchase program, completion expected in Q2 2026

Result Drivers

COMMERCIAL CHANNEL GROWTH - Driven by timing of 2025 shipments to international customers and growth in the Integrity Implant System

OEM CHANNEL DECLINE - Reflects anticipated U.S. OA Pain Management pricing dynamics

GROSS MARGIN EXPANSION - Attributed to favorable product mix and operating leverage

Company press release: ID:nGNX4wVVz8

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$30.62 mln
$28.88 mln (2 Analysts)
Q4 Adjusted EPS
Beat
$0.31
-$0.22 (2 Analysts)
Q4 Net Income
$292,000
Q4 Gross Profit
$19.18 mln
Q4 Income from Operations
$646,000
Q4 Pretax Profit
$764,000


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Anika Therapeutics Inc is $16.00, about 46.3% above its February 25 closing price of $10.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)